Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune...
responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(5259)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 12, 2024 10:54am
RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway
April 12, 2024 - " ..... a few key themes became apparent at the American Association for Cancer Research’s annual meeting [AACR24]. First and foremost, the programs presented are
...more
(1187)
•••
Azzak34
X
View Profile
View Bullboard History
Comment by
Azzak34
on Apr 12, 2024 10:47am
RE:RE:RE:RE:My my!…The entire basher team is working overtime tonight!
Oh I've checked, I can't wait to share my findings with the class. It's hilarious!! What are your current positions Mr Burry? You've continued to tell us all retrospectively
...more
C.RVV Announces Type C Meeting Request Granted by FDA for Clinical Study
posted Apr 24, 2024 9:00am by
Revive Therapeutics Ltd.
-
|
Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA ...read more
(843)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Apr 12, 2024 10:23am
Lots of useless chatter overtop of my post/worth a repost
It has been a long time of silence, with anything related to upcoming phase 3. That being either the pancreatic or MBc Cancers. In the background the science, AKA on- going trial(s) & various
...more
(67)
•••
Quentin30
X
View Profile
View Bullboard History
Comment by
Quentin30
on Apr 12, 2024 10:09am
RE:RE:RE:RE:RE:RE:RE:RE:RE:Type C Meeting Timings
And that is your only response.. Isn't it time for you to post some details of some spurious trial with the vaguest of connections to ONCY.. I hear the local laundromat was bought by another
...more
(67)
•••
Quentin30
X
View Profile
View Bullboard History
Comment by
Quentin30
on Apr 12, 2024 10:07am
RE:RE:RE:My my!…The entire basher team is working overtime tonight!
Glad you feel the need to check Wazzak. So you'll do plenty of due diligence on a random poster from a message board... but blindly pump ONCY and its cheerleaders. Yup - most sensible.
(1187)
•••
Azzak34
X
View Profile
View Bullboard History
Comment by
Azzak34
on Apr 12, 2024 3:43am
RE:RE:My my!…The entire basher team is working overtime tonight!
Huh? What just happened to you? Moon landings and flat earth. Quenty one of my favourite things is when policitans contradict and argue with previous talking points of theirs. Get ready baby
...more
(5259)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 11, 2024 9:25pm
RE:CD8+ TiLs and T-cell exhaustion
ONCY's drug platform pelareorep is part of that promising future referenced in the previous post. In particular, ONCY's AWARE-1 study showed that pelareorep treatment upregulated
...more
(5259)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 11, 2024 9:16pm
RE:AACR 2024 : Cancer vaccines get reintroduction with pathway
April 10, 2024 - A session at the American Association for Cancer Research (AACR) annual meeting posed a key question: Are cancer vaccines ready for prime time? If you ask Scott Kopetz, M.D., Ph.D
...more
(5259)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 11, 2024 9:13pm
RE:RE:RE:FDA ready to review novel cancer vaccine Platform Technology
April 03, 2024 https://www.fiercebiotech.com/biotech/were-open-business-fdas-peter-marks-says-agency-ready-review-novel-cancer-vaccines-despite
(5259)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 11, 2024 9:12pm
RE:FDA ready to review novel cancer vaccine Platform Technology
Repost : - The FDA's Peter Marks believes the FDA’s yet-to-be-formalized platform technology designation could be helpful. The FDA recently issued
...more
(5259)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 11, 2024 9:08pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:Type C Meeting Timings
Employing biomarkers and surrogate endpoints in Orphan/Rare diseases, like in metatstatic breast cancer, result in smaller registration studies and more particularly opens the door for "
...more
(26)
•••
ONCInvestor
X
View Profile
View Bullboard History
Comment by
ONCInvestor
on Apr 11, 2024 9:01pm
RE:Phase III for mBC Trial
Thanks for all of your work on this Quentin, including your review of the corporate presentation. Really good work.
(5259)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 11, 2024 9:01pm
RE:RE:RE:RE:RE:RE:RE:RE:Type C Meeting Timings
So Quentin30 believes in Jehovah ... interesting !!
(67)
•••
Quentin30
X
View Profile
View Bullboard History
Comment by
Quentin30
on Apr 11, 2024 8:42pm
RE:My my!…The entire basher team is working overtime tonight!
Peladawn... only a Sith deals in extremes..!! I suppose the earth is flat and the moon landings faked... which kinda begs the question... if they faked the moon landing... why did they
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Discover a Green Resources Stock Scoring Record Quarterly Growth
Stage Set for Creation of a Leading Intermediate Gold Producer